Sutro Biopharma (STRO) News Today → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free STRO Stock Alerts $4.15 +0.22 (+5.60%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 7:31 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)May 16 at 6:56 AM | americanbankingnews.comSutro Biopharma, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.09) Per Share (NASDAQ:STRO)May 16 at 6:56 AM | americanbankingnews.comSutro Biopharma, Inc. to Post Q2 2024 Earnings of ($0.99) Per Share, HC Wainwright Forecasts (NASDAQ:STRO)May 16 at 5:04 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Rating Reiterated by HC WainwrightMay 16 at 5:04 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Rating Reiterated by WedbushMay 15 at 4:30 PM | markets.businessinsider.comBuy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for LuveltaMay 15 at 12:39 PM | marketbeat.comSutro Biopharma's (STRO) "Outperform" Rating Reaffirmed at OppenheimerOppenheimer reiterated an "outperform" rating and set a $10.00 price target on shares of Sutro Biopharma in a report on Wednesday.May 14 at 8:30 AM | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13 at 10:29 PM | msn.comSTRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024May 13 at 4:30 PM | globenewswire.comSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13 at 10:09 AM | finance.yahoo.comThe past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitableMay 12, 2024 | americanbankingnews.comBank of America Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)May 12, 2024 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Buy" from AnalystsMay 8, 2024 | markets.businessinsider.comExpert Outlook: Sutro Biopharma Through The Eyes Of 10 AnalystsMay 8, 2024 | msn.comB of A Securities Initiates Coverage of Sutro Biopharma (STRO) with Buy RecommendationMay 8, 2024 | msn.comBofA starts Sutro at buy, cites ovarian cancer drug candidateApril 30, 2024 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Given "Outperform" Rating at WedbushWedbush reaffirmed an "outperform" rating and issued a $8.00 price target on shares of Sutro Biopharma in a research report on Tuesday.April 30, 2024 | globenewswire.comSutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 TrialApril 17, 2024 | msn.comSutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15April 5, 2024 | marketbeat.comQ1 2024 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Increased by AnalystSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at Wedbush increased their Q1 2024 earnings estimates for shares of Sutro Biopharma in a research report issued on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.73) per share for the quarApril 3, 2024 | marketbeat.comSutro Biopharma's (STRO) "Outperform" Rating Reaffirmed at WedbushWedbush reissued an "outperform" rating and set a $8.00 target price on shares of Sutro Biopharma in a report on Wednesday.April 3, 2024 | marketbeat.comTruist Financial Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $18.00Truist Financial decreased their price objective on shares of Sutro Biopharma from $25.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday.April 3, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising PipelineApril 2, 2024 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 2, 2024 | markets.businessinsider.comIpsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln DealApril 2, 2024 | msn.comIpsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADCApril 2, 2024 | globenewswire.comSutro Biopharma Announces Pricing of $75 Million Underwritten OfferingApril 2, 2024 | marketwatch.comIpsen, Sutro Biopharma Enter Into Licensing Deal Valued at Up to $900 MlnApril 2, 2024 | globenewswire.comIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsApril 1, 2024 | msn.comPenny Stock Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech InvestorsMarch 28, 2024 | marketbeat.comHC Wainwright Brokers Lower Earnings Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO)Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at HC Wainwright lowered their Q1 2024 earnings per share (EPS) estimates for shares of Sutro Biopharma in a note issued to investors on Tuesday, March 26th. HC Wainwright analyst A. Fein now expects that the company will post earningsMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)March 27, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Sutro BiopharmaMarch 27, 2024 | finance.yahoo.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic AdvancesMarch 27, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)Oppenheimer reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Sutro Biopharma in a report on Wednesday.March 26, 2024 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Price Target Lowered to $8.00 at WedbushWedbush reduced their target price on Sutro Biopharma from $12.00 to $8.00 and set an "outperform" rating on the stock in a research note on Tuesday.March 26, 2024 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMarch 26, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)March 26, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical PipelineMarch 25, 2024 | investorplace.comSTRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023March 25, 2024 | globenewswire.comSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMarch 9, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $10.78 Million Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)Adage Capital Partners GP L.L.C. lifted its stake in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 1,275.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,105,132 shares of the company's stockMarch 6, 2024 | marketbeat.comRubric Capital Management LP Sells 703,934 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)Rubric Capital Management LP cut its stake in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,344,810 shares of the company's stock after sellFebruary 26, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Stake Raised by Acadian Asset Management LLCAcadian Asset Management LLC lifted its position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 18.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 773,867 shares of the company's stock after buying an additionalFebruary 16, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 2,610,000 shares, a growth of 8.8% from the January 15th total of 2,400,000 shares. Based on an average daily volume of 908,800 shares, the days-to-cover ratio is currently 2.9 days.February 10, 2024 | msn.comSutro Biopharma Expands Share Offering, Raises $129MFebruary 2, 2024 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Moderate Buy" by AnalystsSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the cJanuary 9, 2024 | markets.businessinsider.comSutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential AmbiguitiesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and BeyondJanuary 5, 2024 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by WedbushWedbush restated an "outperform" rating and set a $12.00 target price on shares of Sutro Biopharma in a research report on Friday. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. STRO Media Mentions By Week STRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.020.55▲Average Medical News Sentiment STRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼202▲STRO Articles Average Week Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adaptimmune Therapeutics News Fennec Pharmaceuticals News Coherus BioSciences News Candel Therapeutics News Poseida Therapeutics News Monte Rosa Therapeutics News Agenus News Metagenomi News Invivyd News Compass Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
